Novartis ( NYSE:NVS ), the Swiss pharmaceutical giant, has made a strategic move in the field of cancer treatment by securing a licensing agreement with Arvinas, a U.S. biotech company. The deal, valued at up to $1.01 billion, grants Novartis access to Arvinas' experimental prostate cancer drug, ARV-766.
This collaboration marks Novartis' ( NYSE:NVS ) continued...
Wyckoff in Daily/Weekly timeframe, we can observe the price took the upside liquidity (bc) before breaking the structure downside.
I'm expecting the price to go back on my grey zone (supply) around 99 before continuing the bearish trend.
First target 88 (sc)
Second target 83 (demand zone)
I will leave the rest running and observe the reation in the demand zone...
Large market players are selling the stock pre-market at or around 99.50. It could be a signal for a stock to decline. Technical analysis and the volume support the idea.
Longing Novartis (NVS): A Strategic Investment Amidst Geopolitical Tensions
This article presents a compelling rationale for considering a long position in Novartis (NVS) stock. The primary driving factor behind this investment strategy is Novartis' close association with Sandoz (SDZ) following the latter's stock debut last week. Sandoz, a subsidiary of Novartis,...
The PEAD projected a bullish outlook for NYSE:NVS after a positive over reaction following its earnings release placing the stock in drift B with an expected accuracy of 60%.
The PEAD projected a bullish outlook for NYSE:NVS after a positive over reaction following its earnings release placing the stock in drift B with an expected accuracy of 50%.
--
This strategy is very good for beginners
--
In today's video, we attacked how to short using this
very same strategy
--
Also, we look at its weak points when using it for shorting
--
Watching this video you will know the
Top 3 Stocks To Buy Right Now
--
But hurry! because by next week 10th April
these stocks will fly out of the nest
--
Watch this...
The PEAD projected a Bullish outlook for $NVS after a Positive over reaction following its earnings release placing the stock in drift B with an expected accuracy of 66.67%.
The PEAD projected a Neutral outlook for $NVS after a Positive Under reaction following its earnings release placing the stock in drift A with an expected accuracy of 100%.
Is Novartis a good candidate for swing trading?
It has been in an almost horizontal trend for 5 years. But it is also possible that it may break up based on fundamental conditions (1). Good product portfolio and pipeline and many blockbuster.
They pay about half of the profits out to the shareholder.
I don't have the stock, but will consider try get into, in...
The PEAD projected a Neutral outlook for $NVS after a Negative Under reaction following its earnings release placing the stock in drift D with an expected accuracy of 77.78%.
Looking to capitalise on momentum created from a bounce from that short term trend line. Limit order at 86.85 above last week's prices. Ultimate target would be the 100 zone for 1:3.5 risk to reward ratio.
The technical figure Triangle can be found in the Swiss company Novartis International AG (NOVN.vx) at daily chart. Novartis International AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. It is one of the largest pharmaceutical companies in the world. Novartis manufactures the drugs clozapine (Clozaril), diclofenac (Voltaren;...
The PEAD projected a Bullish outlook for $NVS after a Negative over reaction following its earnings release placing the stock in drift C with an expected accuracy of 25%.
The technical figure Double Bottom can be found in the Swiss company Novartis International AG (NOVN.vx) at daily chart. Novartis International AG is a Swiss multinational pharmaceutical corporation. It is one of the largest pharmaceutical companies in the world. Novartis manufactures the drugs clozapine (Clozaril), diclofenac (Voltaren), carbamazepine (Tegretol),...
Immediate targets 94, 95. Invalidation 79.
We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in green with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels...
The PEAD projected a Neutral outlook for $NVS after a Positive Under reaction following its earnings release placing the stock in drift A with an expected accuracy of 100%.
